Dealing with large-scale supply lines when introducing new regimens

Curr Opin HIV AIDS. 2017 Jul;12(4):408-413. doi: 10.1097/COH.0000000000000387.

Abstract

Purpose of review: As programs plan the introduction of a new antiretroviral as part of a regimen for HIV treatment, supply chain considerations need to be taken into account. The key to success is balancing the introduction of a new regimen with the phasing out of an old regimen in a manner that does not result in either a shortage or an excess supply of either product while ensuring that patients continue receiving their medications. This necessitates that country programs, donors, and procurement entities possess an appreciation of the global antiretroviral market and understand the dynamics that the manufacturing of new antiretrovirals will have on the transition.

Recent findings: Supply, demand, and financial considerations affect the capacity of the supply chain to facilitate a successful antiretroviral transition. Although this commentary draws on United States Agency for International Development experiences under the President's Emergency Plan for AIDS Relief from earlier antiretroviral treatment shifts, the approaches are applicable to other institutions and to future transitions. Three approaches were employed: ensuring the engagement of all key stakeholders in transition planning and execution, including clinicians, advocacy groups, supply chain professionals, ministry, and donors; conducting and updating regularly the national quantification and supply plans for all regimens; and introducing antiretroviral products into programs from regional warehouses based on firm orders.

Summary: Extensive planning and accounting for supply chain factors is essential to ensuring a smooth transition to a new regimen and to enable the global antiretroviral market to respond adequately.

Publication types

  • Review

MeSH terms

  • Anti-Retroviral Agents / economics
  • Anti-Retroviral Agents / supply & distribution*
  • Anti-Retroviral Agents / therapeutic use*
  • Drug Industry
  • Government Programs / economics*
  • HIV Infections / drug therapy*
  • HIV Infections / economics
  • Health Services Accessibility
  • Humans
  • Marketing*
  • Workforce
  • World Health Organization

Substances

  • Anti-Retroviral Agents